Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Howard L KaufmanLawrence H SchwartzWilliam N WilliamMario SznolKyle FahrbachYingxin XuEric MassonAndrea Vergara-SilvaPublished in: Journal of cancer research and clinical oncology (2018)
PFS was an imperfect surrogate for OS. Predictive value of 6-month PFS HR for OS HR in the single-agent ICB analysis requires further exploration.